Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female.
Aged 18-64 years (both inclusive) at the time of signing informed consent.
Diagnosed with type 2 diabetes mellitus greater than equal to (≥) 180 days prior to the day of screening.
Glycosylated haemoglobin (HbA1c) of 7.0 - 10.5 percentage (%) \[53 - 91 millimoles per mole (mmol/mol)\] (both inclusive).
Body Mass Index (BMI) ≥ 27.0 kilograms per meter square (kg/m\^2).
Stable daily dose(s) ≥ 90 days prior to the day of screening of any metformin formulations.
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to day of screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Renal impairment measured as estimated glomerular filtration rate (eGFR) value of less than (\<) 30 milliliters per minute (mL/min)/1.73 meter square (m\^2) at screening.
